1. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Issue 2 (February 2021) Authors: Pignata, Sandro; Lorusso, Domenica; Joly, Florence; Gallo, Ciro; Colombo, Nicoletta; Sessa, Cristiana; Bamias, Aristotelis; Salutari, Vanda; Selle, Frédèric; Frezzini, Simona; De Giorgi, Ugo; Pautier, Patricia; Bologna, Alessandra; Orditura, Michele; Dubot, Coraline; Gadducci, Angiolo; Mammoliti,... Journal: Lancet oncology Issue: Volume 22:Issue 2(2021) Page Start: 267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗